A Phase 3 interventional study of Berobenatide and Placebo in Obesity, Overweight and/or Obesity and Knee Osteoarthritis, sponsored by Pfizer. Recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing berobenatide in Obesity — 11 open to participants now, 15 under way, 12 of them phase 3. berobenatide · Obesity.
Among the 21 studies testing berobenatide in Obesity, this one is the 5th largest by planned enrollment, is one of 15 that started in 2026, is one of 12 in phase 3, reaches primary completion later than 10 of the 14 other live ones, and was the 19th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →11 of the 21 studies testing berobenatide in Obesity are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in China
Ages 18+
Pfizer · Sites in United States, Canada
Ages 18+
Pfizer · Sites in United States
Ages 18+ · Healthy volunteers
Pfizer · Sites in Japan
Ages 18+
Pfizer · Sites in United States, Australia
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 5 · Phase 3 12
First in 2024; this study’s year is marked. 15 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 756 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 258 across the 21 interventional studies. Of the 6 that completed or were terminated, 1 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 21 have an industry lead sponsor. The 2 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
64 studies in Obesity by Pfizer: 13 open now, 19 under way, 12 of them phase 3. Of 43 finished, 11 (26%) have results posted.
Among the 64 studies in Obesity by Pfizer, this one is the 10th largest by planned enrollment of the 62 interventional ones that give a count, is one of 19 that started in 2026, is one of 16 in phase 3, reaches primary completion later than 13 of the 18 other live ones, and was the 62nd registered.
Pfizer’s Obesity studies by the year they started, since 2004.
5 of the studies testing berobenatide in Obesity that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07311850Phase 3PfizerEfficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity | 2027-09-21 |
| NCT07400653Phase 3PfizerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | 2027-10-12 |
| NCT07508241PfizerA Study to Learn About the Effect of Study Medicine Called PF-08653944 on How Quickly the Stomach Empties Its Content in Healthy Adults With Overweight or Obesity | 2027-01-27 |
| NCT07845513PfizerA Study to Learn About the Study Medicine Called PF-08653944 in Otherwise Healthy Chinese Adults With Overweight or Obesity | 2027-02-21 |
| NCT07876531PfizerA Study to Learn How Different Forms of the Study Medicine Called Berobenatide is Taken up Into the Blood in Adults With Overweight or Obesity | 2027-04-06 |
Add all 5 to your calendar (.ics) → With an account.
Among the 21 studies testing berobenatide in Obesity, from their registry updates:
Among Pfizer’s 64 in Obesity:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical study is to learn about the safety and effects of berobenatide (PF-08653944) for the treatment of knee osteoarthritis in adults with overweight or obesity with and without type 2 diabetes. The study will last 52 weeks and compare the effects of berobenatide compared to placebo on knee pain, physical function, and body weight. Study activities will include blood tests, knee pain assessment, physical function questionnaires and body measurements.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
value at Screening of:
Exclusion Criteria
For participants with T2D at Screening only:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo
Drug: Placebo
Berobenatide Once Weekly
Drug: Berobenatide
Berobenatide Once Weekly
Drug: Berobenatide
Berobenatide Once Weekly
Drug: Berobenatide
Subcutaneous Injection
Also known as: MET097, PF-08653944
Subcutaneous Injection
Change from Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale score
Time frame: Baseline and Week 52
Percent change from baseline in Body Weight
Time frame: Baseline and Week 52
Change From Baseline in High-Sensitivity C-Reactive Protein
Time frame: Baseline and Week 52
Change from baseline in WOMAC Physical Function Subscale score
Time frame: Baseline and Week 52
Percentage of participants with ≥50% reduction in the WOMAC pain subscale score
Time frame: Baseline and Week 52
Percentage of participants with ≥30% reduction in the WOMAC pain subscale score
Time frame: Baseline and Week 52
Proportion of participants with utilization of protocol specified pain medication during the washout period
Time frame: Baseline and Week 52
Amount of protocol specified pain medication during the washout period
Time frame: Baseline and Week 52
Change from baseline in WOMAC stiffness score
Time frame: Baseline and Week 52
Change from baseline in WOMAC total score
Time frame: Baseline and Week 52
Proportion of participants achieving ≥50% reduction in the WOMAC physical function subscale score
Time frame: Baseline and Week 52
Proportion of participants meeting OMERACT-OARSI
Time frame: Baseline and Week 52
Change from baseline in Average Pain Intensity-Numerical Rating Score
Time frame: Baseline and Week 52
Change from baseline in Worst Pain Intensity -Numerical Rating Score
Time frame: Baseline and Week 52
Change from baseline in SF-36 domain scales and component summary scales
Time frame: Baseline and Week 52
Change from baseline in Body Weight
Time frame: Baseline and Week 52
Change from Baseline in Body Mass Index
Time frame: Baseline and Week 52
Number of participants with Treatment Emergent Adverse Events (TEAEs)
Time frame: Baseline and Week 52
Number of Participants with Serious Adverse Events (SAE)
Time frame: Baseline and Week 52
Number of Participants with AE leading to permanent discontinuation from study intervention or study
Time frame: Baseline and Week 52
Number of Participants with Adverse Events of Special Interest (AESI)
Time frame: Baseline and Week 52
Number of Participants with Clinical laboratory abnormalities
Time frame: Baseline and Week 52
Change from baseline in timed walking distance at Week 52
Time frame: Baseline and Week 52
Percentage of Participants Reporting Improvement in Patient Global Impression of Severity (PGI-S) for knee-OA related physical function
Time frame: Baseline and Week 52
Percentage of Participants Reporting Improvement in Patient Global Impression of Severity (PGI-S) for knee-OA pain
Time frame: Baseline and Week 52
Percentage of Participants Reporting Improvement in Patient Global Impression of Change (PGI-C) for knee-OA related physical function
Time frame: Baseline and Week 52
Percentage of Participants Reporting Improvement in Patient Global Impression of Change PGI-C for knee-OA pain
Time frame: Baseline and Week 52
Change From Baseline in EuroQol 5-Dimension, 5-Level (EQ-5D-5L) Index Score
Time frame: Baseline and Week 52
Change From Baseline in EuroQol-visual analog scale (EQ-VAS) Score
Time frame: Baseline and Week 52
Change From Baseline in Work Productivity and Activity Impairment - General Health (WPAI:GH) Absenteeism Score
Time frame: Baseline and Week 52
Change From Baseline in WPAI:GH Presenteeism Score
Time frame: Baseline and Week 52
Change From Baseline in WPAI:GH Work Productivity Loss Score
Time frame: Baseline and Week 52
Change From Baseline in WPAI:GH Activity Impairment Score
Time frame: Baseline and Week 52
Change From Baseline in Systolic Blood Pressure (SBP)
Time frame: Baseline and Week 52
Change From Baseline in Diastolic Blood Pressure (DBP)
Time frame: Baseline and Week 52
Change From Baseline in Total Cholesterol
Time frame: Baseline and Week 52
Change From Baseline in High-density lipoprotein cholesterol (HDL-C)
Time frame: Baseline and Week 52
Change From Baseline in Low-density lipoprotein cholesterol (LDL-C)
Time frame: Baseline and Week 52
Change from baseline in Non-HDL Cholesterol
Time frame: Baseline and Week 52
Change from baseline in Very low-density lipoprotein cholesterol (VLDL) Cholesterol
Time frame: Baseline and Week 52
Change from baseline in Triglycerides
Time frame: Baseline and Week 52
Change from Baseline in HbA1c (%) (T2D participants only)
Time frame: Baseline and Week 52
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Started Oct 2026 (actual). Primary completion is estimated for Aug 2028, 21 months after the start.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 21 months is close to that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Berobenatide